Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies.
Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013 Jul 05; 341(6141):88-91.
View in:
PubMed
subject areas
Adjuvants, Immunologic
Animals
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm
Antigens, Differentiation
CD47 Antigen
Cell Line, Tumor
Directed Molecular Evolution
Humans
Immunotherapy
Macrophage Activation
Mice
Neoplasms
Phagocytosis
Receptors, Immunologic
Rituximab
authors with profiles
Engin Ozkan